There are many active research projects accessing and applying shared ADNI data. Use the search above to find specific research focuses on the active ADNI investigations. This information is requested annually as a requirement for data access.
Principal Investigator | |
Principal Investigator's Name: | Christopher Edgar |
Institution: | Cogstate |
Department: | Clinical Science |
Country: | |
Proposed Analysis: | Analyses of Cogstate cognitive outcome data. Analyses are planned to occur in four main stages: 1. Feasibility/completion rate analyses (all data) 2. Cross-sectional description of Cogstate outcomes (baseline) 3. Longitudinal description of Cogstate outcomes (changes from baseline) 4. Correlation of Cogstate findings (baseline and longitudinal changes from baseline) with clinical and biomarker data Related study hypotheses from the ADNI 3 NIA proposal: • Hypothesis 2. Early stage AD cognitive decline predicts later functional and clinical decline. Trials in preclinical AD generally utilize composite cognitive measures as sole primary outcome measures, since functional and clinical decline at this stage is minimal. To establish clinical meaningfulness of cognitive change in preclinical AD requires evidence that such change is related to the functional decline at later stages of disease. Long-term follow-up is necessary to establish this link • Hypothesis 3. The course of cognitively normal and MCI participants will be influenced by APOE genotype, baseline cognitive and functional performance, cerebrospinal fluid amyloid and tau biomarkers, and amyloid and tau PET scan results • Hypothesis 4. AD-related cognitive decline can be captured by unsupervised web-based testing at the preclinical and prodromal stages, and web-based registries will facilitate recruitment for ADNI (and therapeutic trials) |
Additional Investigators |